[ad_1]
and the Editors
have repeatedly called for closer collaborations in global health. China has been taking decisive, albeit difficult, measures to prevent and manage outbreaks in diverse settings, from city epicentres to rural clusters. Although these policies might be draconian, they resulted in community solidarity and success; with one prerequisite to both solidarity and success being transparency embraced by both the government and the health profession.
in any public gathering—a limit that was relaxed in June, 2020, probably prematurely. Of course, correlation is no proof of causation.
China’s Ad5-vectored COVID-19 vaccine
has been approved for use in the military after accelerated phase 3 trials. BBIBP-CorV,
which contains inactivated SARS-CoV-2, is an equally promising vaccine candidate.
,
About a third of the carriers had cycle threshold values above 35, suggesting spontaneous recoveries, whereas another third had cycle thresholds of 29 or less, indicative of infectivity.
To assist with the programme Chinese media reported that more than 570 clinicians came from neighbouring provinces and worked 12 h shifts, sometimes allegedly wearing adult diapers and eating only one full meal a day to meet demands.
This work was inspired by the Chinese experience. More than half of Beijing’s 23 million people were tested, with a focus on workers in high-risk occupations, followed by a comprehensive assessment of residents in specific districts with new cases. Beijing has had daily new cases in the low tens since Aug 5, 2020. In adopting similar though less severe measures like compulsory testing and buildings lockdown, Hong Kong has also maintained low cases, suggesting that the Chinese intervention model transcends political structure.
I declare no competing interests.
References
- 1.
Offline: COVID-19 and the dangers of Sinophobia.
Lancet. 2020; 396: 154
- 2.
COVID-19 and China: lessons and the way forward.
Lancet. 2020; 396: 213
- 3.
Covid-19: why Hong Kong’s ‘third wave’ is a warning.
- 4.
China’s Xi pledges $2 billion to help fight coronavirus.
- 5.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet. 2020; 396: 479-488
- 6.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Lancet Infect Dis. 2020; 21: 39-51
- 7.
Government strongly rebuts fallacious comments on Universal Community Testing Programme.
- 8.
Hong Kong embarks on mass Covid testing amid criticism.
- 9.
A narrative systematic review of the clinical utility of cycle threshold values in the context of COVID-19.
Infect Dis Ther. 2020; 9: 573
- 10.
Mainland COVID-19 testing team works 24/7 to help fight COVID-19 in Hong Kong.
Article Info
Publication History
Published: 22 January 2022
Identification
Copyright
© 2020 Elsevier Ltd. All rights reserved.
ScienceDirect
Linked Articles
- Offline: COVID-19 and the dangers of Sinophobia
-
One of the most productive experiences editors at The Lancet have had during the past 6 months has been the intense collaborations with medical and public health scientists in mainland China and Hong Kong. Cooperation began early in the pandemic. During the last week of January, The Lancet published five research papers from mainland China and Hong Kong describing the clinical presentation of patients with COVID-19, human-to-human transmission, genomic relatedness to the SARS coronavirus, and the risks of a global pandemic.
Full-Text
PDF
-
[ad_2]
Source link
